Image Guided Radiotherapy Industry Research Report- forecast till 2030

Pune, India, December 11, 2022/MRFR Press Release/- Market Research Future published a Half - Cooked research report on “Global Imaging Guided Radiotherapy Market Research Report - Forecast to 2030”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2030. 

TOSHIBA CORPORATION (Japan), ViewRay (US), Hitachi, Ltd. (Japan), Siemens AG (Germany), General Electric Company (US), Varian Medical Systems, Inc. (US), Vision RT Ltd. (UK), C-RAD (Sweden) Scranton Gillette Communications (US), XinRay Systems (US), and Koninklijke Philips N.V. (Netherland) are some of the prominent players at the forefront of competition in the Global Imaging Guided Radiotherapy Market and are profiled in MRFR Analysis. 

Global Imaging Guided Radiotherapy Market    - Overview

The Global Imaging Guided Radiotherapy (IGRT) Market is growing exponentially owing to the rising prevalence of cancer and growing demand for advanced therapies are the major factor driving the The Image Guided Radiotherapy market is anticipated to reach USD 4,854.6 Million by 2030 at 14.7% CAGR during the forecast period 2022-2030

According to WHO, the number of patients who are presently living after a cancer diagnosis has increased compared to the past when cancer biological therapies was not available or less practiced in the healthcare industry. As per WHO the average healing rate for the US in 2013 was 196.1 in males for all ages the global rate for cancer survivors is also increasing, this number of cancer survivals has improved since the innovation of cancer biological therapies and this factor will continue to assist the growth of the cancer biological therapies market.

At the molecular level, cancer is a genetic disease that develops due to mutation of genes in somatic cells. The growing rates of different types of cancers calls for new and advanced treatments options. These developing therapies for cancer will have huge demand, as cancer is the 2nd largest reason for deaths in the world (as per WHO).

Industry Updates

Nov, 2017 ViewRay, Inc. has successfully installed the MR-Guided Radiotherapy System in Washington University. This initiative is expected to increase the customer base for ViewRay Inc. and strengthen its position in USA.

 Nov, 2017 ViewRay, Inc. has successfully installed the MRIdian® Linac in Rigshospitalet and Herlev Hospitals, Denmark. This initiative is expected to strengthen its market in Europe.

 Dec, 2017 Varian’s Halcyon Treatment System, an image guided radiotherapy has recently received ANVISA Registration from Brazil. With this approval Varian has expanded its reach in Latin America and has the opportunities to increase the overall customer base.

 June, 2016 Merck to acquire afferent pharmaceuticals in a deal where Merck will acquire a privately held afferent pharmaceutical’s. Afferent pharmaceuticals is a leader in the development of therapeutic, thus this acquisition will benefit Merck and strengthen their therapeutic segment.

 Global Imaging Guided Radiotherapy Market    -

Regional Analysis

According to regions, the global Imaging Guided Radiotherapy Market is dominated by North America. The factor contributing for its growth includes   the rising medical tourism and increasing healthcare sector privatization in this region. According to National Institute of Health (NIH) it has been found that in 2016, a projected 1,685,210 new cases of cancer will be detected in the United States and 595,690 individuals will die from the disease which further increases the growth of the market.

Moreover the prevalence of chronic disease is increasingly spreading in North American countries, For example according to survey of National Center for Chronic Disease Prevention and Health Promotion (CDC) in United States every year 7 out of 10 individuals die due to chronic diseases and 86% of healthcare costs in the country. With cancer biological therapy playing a primary role for patients treatment and enhancing the market for North America region.

In 2014, European Society for Medical Oncology estimated the cost burden of cancer and estimated around 110 to 120 billion euros. Germany accounted for approximately 20% to 26% of total cost. As per the Associations of European Cancer League, 3 million new cancer cases occur in 38 European countries. Breast cancer and prostate cancer has been diagnosed within one third of European population. Many European cancer organizations including cancer Immunology & Immunotherapy Center (CIIC) are strategizing collaborations with developing countries in Europe with the aim to improve diagnosis and therapeutic treatment for different types of cancer, particularly including prostate and breast cancer for Europe

Asia-Pacific market is expect to be the fastest growing market. This high growth is mainly attributed due to increasing R&D funding by the developing countries like China and India for the development of healthcare sector. The various others factors that influence the growth of the market include growing incidence of cancer, aging population, Increasing demand for advanced therapies, patent expiry of leading drugs, government initiatives and increasing public awareness about various diseases and treatment options.

Browse Full Report @ https://www.marketresearchfuture.com/reports/image-guided-radiotherapy-market-4276